Your session is about to expire
← Back to Search
Rucaparib + Nivolumab for Small Cell Lung Cancer
Study Summary
This trial will test a new combination of drugs to see if it can help people with small cell lung cancer live longer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have hepatitis B or hepatitis C virus infection when being checked before the study.My small cell lung cancer is in stage IV, and I've responded well to my first round of chemotherapy.I have not had major surgery in the last 4 weeks.I do not have active lung inflammation or scarring.I have another type of cancer that is currently active.I still have side effects from previous cancer treatments.I have not received any live vaccines within 4 weeks before starting nivolumab.You are allergic to the study drugs.My liver is functioning well.I have previously received treatment with drugs that target immune checkpoints.I finished my 4th chemotherapy cycle less than 6 weeks ago.You have an autoimmune disease.I am living with HIV/AIDS.My bone marrow is working well.I can take care of myself and am up and about more than half of my waking hours.I am currently being treated for an infection.I am currently taking immunosuppressant medication.My cancer has spread to my brain or spinal cord and hasn't been treated.I have a heart condition.
- Group 1: Patients with Stage IV SCLC
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are engaged in this research?
"Affirmative. Clinicaltrials.gov data reveals that this investigation, which was inaugurated on September 4th 2019, is actively enrolling participants. 36 volunteers are necessary between 1 trial site."
What medical conditions have been treated with the combination of Rucaparib and Nivolumab?
"This combination drug is employed to treat malignant neoplasms and has been seen to be efficacious in treating conditions such as non-operable melanoma, squamous cell carcinoma, and metastasized esophageal adenocarcinomas."
Have Rucaparib and Nivolumab been given the regulatory go-ahead by the FDA?
"While there is evidence to suggest a degree of safety, considering this experiment is only at Phase 2, the safety rating for Rucaparib and Nivolumab has been calculated as 2."
Have there been any investigations focusing on the combination of Rucaparib and Nivolumab?
"Currently, there are 87 Phase 3 studies examining the effects of Rucaparib and Nivolumab with 743 live trials in total. Columbus, Ohio is a popular hub for this research but it can be found at over 41991 locations across the globe."
Is enrollment still open for this medical research?
"Clinicaltrials.gov reports that this medical trial is still open to applicants and was initially posted on the 4th of September 2019, with its last update taking place on November 10th 2022."
Is this a pioneering or groundbreaking trial?
"Since 2012, studies have been conducted to investigate the application of Rucaparib and Nivolumab. Commencing with a 659-subject trial sponsored by Ono Pharmaceutical Co. Ltd., this drug has since advanced through Phase 1 & 2 trials and is now being used in 743 live experiments across 2389 cities and 49 countries worldwide."
Share this study with friends
Copy Link
Messenger